hSulf-1 inhibits cell proliferation and migration and promotes apoptosis by suppressing stat3 signaling in hepatocellular carcinoma

LING LIU 1, FENG DING 2, JIWEI CHEN 1, BOYONG WANG 1 and ZHISU LIU 1

1Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071; 2Department of Clinical Laboratory, Wuhan Puai Hospital, Wuhan, Hubei 430033, P.R. China

Received June 18, 2013; Accepted December 6, 2013

DOI: 10.3892/ol.2014.1848

Abstract. Human sulfatase-1 (hSulf-1) has been shown to desulfate cellular heparin sulfate proteoglycans and modulate several growth factors and cytokines. However, hSulf-1 has not been previously shown to mediate the signal transducer and activator of transcription 3 (stat3) signaling pathway, which is known to regulate cell proliferation, motility and apoptosis. The present study investigated the role of hSulf-1 in stat3 signaling in hepatocellular cancer. hSulf-1 expression vector and stat3 small interfering RNA (siRNA) were constructed to control the expression of hSulf-1 and stat3 in HepG2 cells. hSulf-1 was found to inhibit the phosphorylation of stat3 and downregulate its targeted protein. MTT and Transwell chamber assays, as well as Annexin V/propidium iodide double-staining methods, were used to examine the effects of hSulf-1 on stat3-mediated motility, proliferation and apoptosis in HepG2 cells. Transfection with hSulf-1 cDNA and/or stat3 siRNA inhibited cell proliferation and motility, concurrent with G1/G0 and G2/M phase cell cycle arrest and apoptosis. Overall, the results of the current study suggested that hSulf-1 functions as a negative regulator of proliferation and migration as well as a positive regulator of apoptosis in hepatocellular carcinoma, at least partly via the downregulation of stat3 signaling.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide and the incidence of this cancer has been increasing in recent years (1,2). Improvements in survival are likely to depend on an improved understanding of the molecular processes involved in tumorigenesis and metastasis in hepatocellular cancer.

Human sulfatase 1 (hSulf-1), previously characterized as a heparin-degrading endosulfatase, negatively regulates growth factor and cytokine signaling and proteolysis by desulfation of cell surface heparin sulfate proteoglycans (HSPGs), major constituents of the extracellular matrix (3-6). This biological effect requires sulfation of defined sites on glycosaminoglycan chains. Previous studies have demonstrated that hSulf-1 is downregulated in cancer cell lines originating from various types of human cancer, including ovarian, breast, renal and HCC, and that its expression is regulated by epigenetic mechanisms including DNA methylation and histone acetylation (7-10).

Additionally, previous studies have demonstrated that re-expression of hSulf-1 in ovarian cells suppresses fibroblast growth factor (FGF)-2 and heparin-binding epidermal growth factor (HB-EGF) signaling and inhibits cell proliferation and invasion in vitro (11-14). Further studies of the role of hSulf-1 in tumorigenesis and progression have also found that expression of hSulf-1 inhibits hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) signaling (15-18). While signal transducer and activator of transcription 3 (stat3) signaling is known to be activated by several growth factor receptors, including epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), which are important in cell proliferation, migration, apoptosis and angiogenesis (19-20), no previous studies have found a role for hSulf-1 in regulating the stat3 signaling pathway.

Since the stat3 signaling pathway is one of the most important signal transduction cascades characterized to date and is known to be involved in the regulation of cytokine receptor signaling in HCC (21-22), the potential link between hSulf-1 and stat3 in HCC must be investigated. Thus, in the current study, to confirm the role of hSulf-1 in the proliferation, migration and apoptosis of HCC, hSulf-1 was re-expressed in HCC cells and stat3 siRNA was constructed to manipulate the expression of this critical signaling molecule in vitro. In addition, the present study sought to determine whether the stat3 pathway is mediated by HGF, a potent mitogen and key regulator of cell proliferation, differentiation and motility in HCC (23-25), in HCC cells exhibiting differential expression...
of hSulf-1. The results indicated that hSulf-1 may inhibit HCC growth and migration through suppression of the stat3 signaling pathway and that the antiproliferative activity of hSulf-1 in HepG2 cells is due to cell cycle arrest and apoptosis.

Materials and methods

Plasmids and siRNA. The plasmid containing whole-length hSulf-1 complementary DNA was purchased from Wuhan Genesil Biotechnology Co., Ltd. (Wuhan, China) and stat3 siRNA was purchased from Origene (Rockville, MD, USA). The stat3 siRNA target sequence used was GCCGTCAGGTC ACTACTA and the control siRNA target sequence used was AATTCTCGAAGCCTGCAAGT. Transfections were performed using Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA).

Cell culture. The HCC cell lines, HepG2, Hep3B, Huh-7 and SMMC-7221, were purchased from Shanghai Cell Bank (Shanghai, China) and were cultured in media according to the manufacturer’s instructions. HepG2 cells stably expressing hSulf-1 were selected with 600 µg/ml G418 (Invitrogen Life Technologies) and the transfection results were detected by western blotting. Cells were maintained at 37˚C in an atmosphere of humidified air with 5% CO₂.

Treatment of cells with trichostatin A (TSA) and 5-aza-dC. All drugs were added the day after the subculture of HepG2 cells. The 5-aza-dC (Sigma-Aldrich, St. Louis, MO, USA) was added at concentrations of 0, 0.5, 1.0, 2.5 and 5.0 µmol/l at 24, 48 and 72 h time points. For TSA (Sigma-Aldrich) treatment, HepG2 cells were treated with TSA concentrations of 0, 0.25 and 0.5 µmol/l and cells were incubated for 24 h. For combined treatment, HepG2 cells were treated with 5.0 µmol/l 5-aza-dC at 24 and 48 h time points and then with 0.5 µmol/l TSA for 24 h. When HepG2 cells were treated with no drug, identical volumes of water were added.

RNA extraction and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was isolated from HCC cells using an RNaseasy kit (Qiagen, Valencia, CA, USA). Taq enzyme and PCR reagents were purchased from Tiangen Corporation (Beijing, China). Primers for amplifying hSulf-1 and GAPDH, which was used as internal control in RT-PCR, were purchased from Sangon Corporation (Shanghai, China). The forward and reverse primers used were as follows: 5'-CTCACAGTCCGGAGCAGGA-3' (forward) and 5'-CACGGCTTTGCCTCTGACCTCC-3' (reverse) for hSulf-1, and 5'-AGTCAACGGATTTGGTCG-3' (forward) and 5'-TTGATTTTGGAGGGATCTG-3' (reverse) for GAPDH. The primers yielded amplicons of 371 and 238 bp, respectively. The PCR conditions used were as follows: 94˚C for 5 min, followed by 34 cycles of 15 sec at 94˚C, 30 sec at 62˚C and 30 sec at 72˚C, followed by a final extension at 72˚C for 10 min. Semi-quantitative RT-PCR products were analyzed on 1% agarose gels stained with ethidium bromide.

Western blotting. HepG2 cells were lysed in RIPA buffer (Beyotime Institute of Biotechnology, Shanghai, China). Cell lysates (20 µg protein/lane) were loaded and separated on gradient polyacrylamide gels and then transferred to polyvinylidene difluoride membranes by electroblotting (Millipore Corp., Boston, MA, USA). Following blocking with 5% non-fat milk containing 0.3% Tween 20 for 1 h, the membranes were incubated overnight with primary antibodies at 4˚C, including anti-hSulf-1 (1:250), -stat3 (1:500), -phospho-stat3 (1:500), -phospho-c-met (1:500), -β-catenin (1:1000) and -cyclin D1 (1:500) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The membranes were washed three times with Tris-buffered saline containing Tween 20 and membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies (R&D Systems China Co., Ltd., Shanghai, China) at 4˚C for 1 h. Subsequently, membranes were exposed to enhanced chemiluminescent reagents for detection of protein bands. β-actin was used as an internal control.

Cell proliferation analysis. Cell proliferation was measured using an MTT assay (Sigma-Aldrich). Cells were harvested and plated in 96-well plates at 4x10⁴ cells/well in 100 µl culture medium and then maintained at 37˚C in an incubator containing 5% CO₂ for three days. In total, 20 µl MTT dye was added to each well (5 mg/ml). After 4 h of incubation, 100 µl dimethyl sulfoxide was added for 10 min to dissolve the crystals. The absorbance was measured by a microtiter plate reader at 490 nm (no. DG5033A, Jinggong Industrial Co., Ltd., Shanghai, China). Cell viability was expressed as an optical density value.

Transwell chamber assay. Migration was detected by the Transwell chamber assay. A total of 5x10⁴ cells per ml were starved overnight in serum-free medium. In total, 100 µl of cells were then added to each upper well in a 24-well Transwell plate (8.0-µm pore size; Corning, Inc., Cambridge, MA, USA) and medium containing 10% fetal bovine serum (600 µl) was added to the lower well. Cells were incubated in the Transwell chambers for 24 h. Then, the Transwells were extracted, the medium in the upper well was removed and the Transwells were washed in phosphate-buffered saline (PBS) once. The residual cells in the upper well were swabbed and stained with 0.5% crystal violet for 20 min. Cells that had migrated through the Transwell were dissolved in 10% acetic acid and the absorbance was measured at 560 nm.

Cell cycle analysis. Cells were seeded at a density of ~6x10⁵ cells/ml and treated with 5 µmol/l cisplatin to determine the effects of hSulf-1 on cisplatin-induced cell cycle arrest for 24 h. Following incubation, cells were washed with PBS and fixed with 70% ethanol overnight at 4˚C. Next, cells were stained with 1 ml propidium iodide (PI, Sigma-Aldrich) synthetic dye solution (20 µg/ml PI, 20 µg/ml RNase, 0.5% Triton X-100 and 1 g/ml sodium citrate) for 30 min at 37˚C in the dark and then analyzed by flow cytometry using an FC 500 MPL instrument (Beckman Coulter, Miami, FL, USA). The cell number in each phase in every group was calculated using ModFit software (Verity Software House Corp., Topsham, ME, USA).

Cellular apoptosis assay. Cells were plated at a density of 6x10⁵ cells/ml. Following treatment with 5 µmol/l cisplatin, apoptotic cells were quantified by Annexin V/PI double staining (Jingmei Biotech Co., Ltd., Shenzhen, China). The
double-staining technique was performed as follows, according to the manufacturer's instructions. Cisplatin-treated cells were collected and then washed twice in cold PBS. Cell pellets were resuspended in 250 µl 1X binding buffer (Jingmei Biotech Co., Ltd.) and resuspended cells were gently vortexed and stained with 5 µl Annexin V-fluorescein isothiocyanate and 10 µl PI for 15 min in the dark at room temperature. The results were analyzed using flow cytometry (PC 500 MPL, Beckmann Coulter, Miami, FL, USA) according to the manufacturer's instructions.

**Statistical analysis.** All data obtained in triplicate independent experiments were evaluated using GraphPad Prism 5.02 for Windows (GraphPad Software, Inc., La Jolla, CA, USA). Data are expressed as the mean ± standard error. The significance of differences between groups was determined by two-sided t-tests. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Expression of hSulf-1 mRNA decreases in HCC cell lines and reactivates with 5-aza-dC and/or TSA in HepG2 cells.** Firstly, the expression of hSulf-1 mRNA was evaluated in four human HCC cell lines (HepG2, Hep3B, Huh-7 and SMMC-7221) by semi-quantitative RT-PCR. All the HCC cell lines tested were found to express low or undetectable levels of hSulf-1 mRNA (Fig. 1A and B). The expression of hSulf-1 increased when treated with 5-aza-dC or TSA in HepG2 cells and also increased due to a synergistic effect of 5.0 µmol/l 5-aza-dC and 0.5 µmol/l TSA combined treatment. ▽P<0.05, vs. control group and ▽▽P<0.05, vs. co-treatment group. Control group, parental cells; hSulf-1, human sulfatase-1; HCC, hepatocellular carcinoma; TSA, trichostatin A.

**hSulf-1 inhibits the phosphorylation of stat3 in HepG2 cells.** Previous studies have shown that dysregulation of the stat3 signaling pathway is involved with HCC development and metastasis. Therefore, the effects of hSulf-1 on the stat3 signaling pathway were investigated in HepG2 cells. The expression of hSulf-1 was detected in hSulf-1-transfected HepG2 cells and control siRNA-transfected HepG2 cells (Fig. 2A and B). The results showed that overexpression of hSulf-1 reduced the phosphorylation of stat3 in HepG2 cells, but did not affect the expression of total stat3 (Fig. 2C and D). Furthermore, when hSulf-1-negative HepG2 cells were treated with 5 ng/ml HGF, the phosphorylation of c-met and stat3 increased. By contrast, in hSulf-1-transfected HepG2 cells, the phosphorylation of c-met and stat3 decreased (Fig. 2E).

**hSulf-1 inhibits the proliferation of HepG2 cells through stat3 signaling.** The effects of the stable transfection of hSulf-1 into hSulf-1-negative HepG2 cells on cell proliferation was examined and measured by MTT assay. The viability of hSulf-1-transfected cells was significantly decreased compared with that of vector-transfected cells (Fig. 3C). To confirm whether the stat3 signaling pathway is involved in mediating these inhibitory effects on cell proliferation, cells were also transfected with stat3 siRNA to knockdown the expression of stat3. The results showed that the inhibitory effects of hSulf-1 on cell proliferation were decreased following the knockdown of stat3 (Fig. 3C). Cyclin D1 protein, a protein involved in proliferation downstream of stat3, was also expressed at extremely low levels following transfection with hSulf-1 (Fig. 3A and B). In addition, following the knockdown of stat3 in hSulf-1-transfected cells, cell viability was further decreased (Fig. 3C). These results suggested that hSulf-1 inhibits HepG2 cell growth by suppressing stat3 signaling.

**hSulf-1 inhibits the migration of HepG2 cells.** To further elucidate the relevance of hSulf-1 function in HCC, the effects of
LING et al.: CORRELATION BETWEEN hSulf-1 AND stat3 SIGNALING IN HCC

hSulf-1 on migration were investigated by Transwell chamber assay. The results showed that hSulf-1 transfection inhibits cell migration ability compared with vector transfection alone. Additionally, stat3 siRNA transfection decreased the migration of HepG2 cells and cells doubly transfected with stat3 siRNA, and the hSulf-1 expression vector exhibited further reductions in migration (Fig. 3D). These results suggested that hSulf-1 may affect stat3-mediated migration.

hSulf-1 induces G0/G1 phase cell cycle arrest through stat3 signaling and promotes G2/M phase cell cycle arrest in HepG2 cells. Next, it was investigated whether the antiproliferative activity of hSulf-1 in HepG2 cells correlates with cell cycle arrest. As demonstrated in Fig. 4A-D, cell cycle analysis revealed that, compared with the vector and control siRNA groups, stat3 siRNA-transfected cells exhibited an increased number of cells in the G0/G1 phase, while the number of cells in the G2/M phase did not change. By contrast, when hSulf-1 was transfected into HepG2 cells, the number of cells in the G0/G1 and G2/M phases was increased. Therefore, it was assumed that hSulf-1 induces G0/G1 phase arrest in HepG2 cells through the stat3 signal pathway and also promotes G2/M phase arrest.

hSulf-1 promotes cisplatin-induced apoptosis in HepG2 cells. Dysregulation of cell growth and apoptosis is considered to lead to carcinogenesis. Therefore, the effects of hSulf-1 on cisplatin-induced apoptosis were examined in HCC cells using Annexin V/PI double-staining. hSulf-1-transfected HepG2 cells showed a higher sensitivity to cisplatin-induced...
apoptosis compared with that in control cells. Furthermore, the apoptosis rate in HepG2 cells was decreased following transfection with stat3 siRNA (Figs. 5A-D and 6A). Consistent with these observations, the expression of the antiapoptotic protein, bcl-2, which signals downstream of stat3, was found to increase in vector-transfected HepG2 cells compared with that in hSulf-1-transfected HepG2 cells (Fig. 6B). The results showed that the hSulf-1 expression promotes cisplatin-induced apoptosis in HepG2 cells and correlates with stat3 signaling to a certain degree.
The present study demonstrated that hSulf-1 suppresses the phosphorylation of Stat3, indicating that hSulf-1 regulates the activity of Stat3. This effect may correlate with the activity of receptor molecules since c-met activates the phosphorylation of Stat3. However, when hSulf-1 was re-expressed following transfection with the hSulf-1 expression vector, c-met expression was also inhibited, thereby further influencing the phosphorylation of Stat3.

In addition, the current study investigated the correlation between hSulf-1 and Stat3 signaling on the effects of cell proliferation, migration and apoptosis. hSulf-1 has been previously shown to inhibit cell growth and invasion through HGF, FGF, HB-EGF, VEGF and Wnt signaling (6,12,29-30). In the present study, when HepG3 cells were transfected with Stat3 siRNA to silence the expression of Stat3, cell viability and motility were decreased to a certain extent. This effect was more apparent following the additional transfection of the HepG2 cells with hSulf-1, suggesting that hSulf-1 is involved in the regulation of cancer cell proliferation and migration, partly due to the inhibition of Stat3 signaling. Consistent with these observations, the expression of cyclin D1, a downstream effector of Stat3 signaling in the regulation of cell proliferation (31), decreased in hSulf-1-transfected HepG2 cells. These results demonstrated that Stat3 activation in cancer cell proliferation and migration is mediated by the effects of hSulf-1.

Next, the present study investigated whether the antiproliferative activity of hSulf-1 in HepG2 cells was due to cell cycle arrest and apoptosis. hSulf-1 was found to induce G0/G1 arrest and apoptosis partly through the Stat3 signaling, and to also promote G2/M phase arrest. The results of the Annexin V/PI double staining demonstrated that hSulf-1 transfection increases the number of apoptotic HepG2 cells. Previous studies have revealed that Stat3 signaling is pivotal in the antiapoptotic process, mediated through downstream proteins, including bcl-2 and bcl-XL, which allow cells to resist apoptosis (32-33). Additionally, Stat3 signaling has been shown to promote G0/G1 phase cell cycle arrest (34-35).

In the current study, cisplatin treatment also induced G0/G1 phase arrest and downregulation of Stat3 signaling in HepG2 cells. Therefore, the effects of hSulf-1 on apoptosis and G0/G1 phase cell cycle arrest may involve downregulation of the Stat3 pathway. Furthermore, it was found that hSulf-1 expression alone induces G2/M phase arrest in HepG2 cells; elucidation of the mechanisms involved requires further investigation.

In conclusion, the results of the present study demonstrated that hSulf-1 re-expression attenuates the phosphorylation of Stat3, suppresses cell proliferation and motility and promotes cancer cell apoptosis. These effects correlate with the downregulation of Stat3 signaling in HepG2 cells. Thus, the study provides a novel insight into the molecular mechanisms of hSulf-1 in HCC cells. These observations strengthen the theory that hSulf-1 is a promising target for therapeutic intervention through the Stat3 signaling pathway in HCC.
References

1. el-Serag HB: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 5: 87-107, 2001.
2. He J, Gu D, Wu X, et al: Major causes of death among men and women in China. N Engl J Med 353: 1124-1134, 2005.
3. Lin X: Functions of heparan sulfate proteoglycans in cell signaling during development. Development 131: 6009-6021, 2004.
4. Park PW, Reizes O and Bernfield M: Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem 275: 29923-29926, 2000.
5. Kirkpatrick CA and Selleck SB: Heparan sulfate proteoglycans at a glance. J Cell Sci 120: 1829-1832, 2007.
6. Kikuchi A and Yamamoto H: Regulation of Wnt signalling by receptor-mediated endocytosis. J Biochem 141: 443-451, 2007.
7. Staub J, Chien J, Pan Y, et al: Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 26: 4969-4978, 2007.
8. Lai J, Chien J, Staub J, et al: Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278: 23107-23117, 2003.
9. Chen Z, Fan JQ, Li J, et al: Promoter hypermethylation correlates with the HSulf-1 silencing in human breast and gastric cancer. Int J Cancer 124: 739-744, 2009.
10. Monneret C: Histone deacetylase inhibitors. Eur J Med Chem 40: 1-13, 2005.
11. Pye DA, Vives RR, Turnbull JE, Hyde P and Gallagher JT: Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 273: 22936-22942, 1998.
12. Lai JP, Chien J, Strome SE, et al: HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23: 1439-1447, 2004.
13. Lai JP, Chien JR, Moser DR, et al: HSulf-1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126: 231-248, 2004.
14. Li J, Kleeff J, Abiatari I, et al: Enhanced levels of HSulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 4: 14, 2005.
15. Dai Y, Yang Y, MacLeod V, et al: HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 280: 40066-40073, 2005.
16. Lai JP, Sandhu DS, Shire AM and Roberts LR: The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J Gastrointest Cancer 39: 149-158, 2008.
17. Narita K, Staub J, Chien J, et al: HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 66: 6025-6032, 2006.
18. Ji W, Yang J, Wang D, et al: HSulf-1 gene exhibits anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers. PLoS ONE 6: e23274, 2011.
19. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2788, 2000.
20. Rahaman SO and Harbor PC: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21: 8404-8413, 2002.
21. Iwamaru A, Szymanski S, Iwado E, et al: A novel inhibitor of the stat3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26: 2435-2444, 2007.
22. Jacoby JJ, Kalinowski A, Liu MG, et al: Cardiomyocyte restricted knockout of stat3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 100: 12929-12934, 2003.
23. Kurdi M and Booz GW: Can the protective actions of JAK-stat in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling. J Cardiovasc Pharmacol 50: 126-141, 2007.
24. Bores P and Miller CM: Heparocyte growth factor: a multifunctional cytokine. Lancet 345: 293-295, 1995.
25. Lee KH, Choi EY, Hyun MS, et al: Role of heparocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis 25: 89-96, 2008.
26. Moore AE, Greenhough A, Roberts HR, et al: HGF/Met signaling promotes PGF2 biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis 30: 1796-1804, 2009.
27. Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K and Emerson CP Jr: Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem 281: 4969-4976, 2006.
28. Diez-Roux G and Ballabio A: Sulfatases and human disease. Annu Rev Genomics Hum Genet 6: 355-379, 2005.
29. Forsten-Williams K, Chu CL, Fannon M, Bucek-Thomas JA and Nugent MA: Control of growth factor networks by heparan sulfate proteoglycans. Ann Biomed Eng 36: 2134-2148, 2008.
30. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM and Emerson CP Jr: Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 293: 1663-1666, 2001.
31. Ornitz, DM: FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22: 108-112, 2000.
32. Fletcher S, Turkson J and Gunning PT: Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 3: 1159 -1168, 2008.
33. Chen Z and Han ZC: STAT3: a critical transcription activator in angiogenesis. Med Res Rev 28: 1-13, 2008.
34. Ornitz, DM: FGFRs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22: 108-112, 2000.
35. Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251: 199-210, 2007.
36. Yu ZY, Huang R, Xiao H, et al: Fluacrypyrim, a novel stat3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active stat3. Int J Cancer 127: 1259-1270, 2010.